The Manifest named Dignitas Digital as one of the most-reviewed software developers in Philadelphia.

The biopharmaceutical business has the potential to provide revolutionary treatments to patients all around the world, despite obstacles including the escalating costs of drug research and regulatory barriers.

Surface Plasmon Resonance (SPR) has revolutionized the way of measuring the binding in molecules, in real-time, without the use of labels.

Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.

Jubilant Biosys is delighted to have Giuliano come on board as we make rapid progress in expanding our drug discovery services and CDMO business through investments in infrastructure and new capacity.

According to Clutch’s 2021 research, Dignitas Digital is ranked amongst the highest-performing software development companies in India.

A showcase of computational chemistry capabilities with emphasis on virtual screening and scaffold-hopping campaigns for first-in-class targets demonstrated through scientific case studies.

Did you know that in the US alone, a new drug can take approximately 12-15 years to get available in the market?

The team Dignitas Digital wants to proudly announce that we have been listed as one of the top software development companies in Pennsylvania by a well-known B2B review-based company Clutch.

Case Study: Small molecule inhibitors of NMMT for treatment of metabolic disorders

Jubilant Biosys has been operating an advanced RapidFire 365 system for several years now. It is an advanced high throughput LC system coupled with an API-5500 mass spectrometer.

Without minimizing the risks, the clinical trials can derail from their initial path, which can even lead to the sponsors losing faith in the trials

Jubilant Biosys Limited announced the completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India.

The rise in the digital landscape in the biopharma industry has allowed them to significantly transform their capabilities and strengthen their processes.

Jubilant Biosys will be discussing the transformation needed in decision-making, assessment, and bringing in scale-up expertise earlier than typically done through PR&D scientists.

Jubilant Biosys, as an integrated Contract Research Organization (CRO), has emerged as a leading collaborator for biotechnology and pharmaceutical companies throughout the world.

Jubilant grants an exclusive license to Lengo Therapeutics, a biopharma company focused on the discovery and development of novel treatments targeting driver mutations in oncology.

A Bangalore-based Contract Research Organization (CRO), Jubilant Biosys selects CDD Vault to communicate research data with customers for the next five years.

Jubilant Biosys is a Contract Research Organization with its R&D centers in India and business offices in Asia and North America.